Early use of higher-efficacy therapies is recommended for patients with moderately to severely active Crohn disease (CD), ...

In the video, Dr. Nicola J. Gullick, a Consultant Rheumatologist in Coventry and one of the investigators on the PRO-SPIRIT ...

Biocon is entering a transformative phase, leveraging regulatory shifts in the US and a strong insulin and GLP-1 portfolio to ...

New guidelines recommend doctors tackle Crohn's disease head-on, calling for the use of cutting-edge drugs as early as ...

The American Gastroenterological Association has released updated guidelines for treating moderate-to-severe Crohn’s disease, outlining 16 evidence-based recommendations that prioritize advanced ...

The American Gastroenterological Association (AGA) has released a comprehensively updated clinical guideline on the ...

New guidelines for Crohn’s disease recommend going to advanced drugs immediately. The guidelines recommend using these drugs ...

T reatment of moderate-to-severe Crohn's disease should prioritize early use of higher-efficacy advanced therapies rather ...

The American Gastroenterological Association's new guideline uses cutting-edge network meta-analyses to recommend prescribing ...

Mirikizumab (Omvoh) is effective in inducing a clinical response in adults with moderate-to-severe ulcerative colitis and ...

Interleukin-23 (IL-23) plays a pivotal role in the complex pathogenesis of both ulcerative colitis and Crohn's disease, making it a promising therapeutic target.1 Mirikizumab is a humanised IgG4 ...

Unequal global access to inflammatory bowel disease (IBD) therapies creates profound health inequities. The increasing prevalence of IBD in Western countries, driven by high incidence rates and low ...